MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: mii-exa-onko-cdk46-class-medication

Raw json | Download

{
  "resourceType" : "MedicationRequest",
  "id" : "mii-exa-onko-cdk46-class-medication",
  "meta" : {
    "profile" : [
      🔗 "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-therapieempfehlung-medikation|2027.0.0-ballot.1"
    ]
  },
  "language" : "de",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"de\" lang=\"de\"><hr/><p><b>German</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: MedicationRequest mii-exa-onko-cdk46-class-medication</b></p><a name=\"de-mii-exa-onko-cdk46-class-medication\"> </a><a name=\"de-hcmii-exa-onko-cdk46-class-medication\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mii-pr-onko-therapieempfehlung-medikation.html\">MII PR Onkologie Therapieempfehlung Medikation</a> version: 2027.0.0-ballot.1</p></div><p><b>status</b>: Active</p><p><b>intent</b>: Option</p><p><b>medication</b>: <span title=\"Codes:{http://fhir.de/CodeSystem/bfarm/atc L01EF}\">CDK4/6 Inhibitor (Klasse L01EF) - Palbociclib, Ribociclib oder Abemaciclib</span></p><p><b>subject</b>: <a href=\"Patient-mii-exa-onko-molecular-board-patient.html\">Maria Müller  Female, DoB: 1968-07-22 ( https://www.medizininformatik-initiative.de/fhir/sid/patienten#MTB-2024-001)</a></p><p><b>authoredOn</b>: 2024-01-15</p><p><b>reasonReference</b>: <a href=\"Condition-primaertumor-example.html\">Condition Bösartige Neubildung: Brustdrüse, nicht näher bezeichnet</a></p><p><b>note</b>: </p><blockquote><div><p>Molekulares Tumorboard empfiehlt beliebigen CDK4/6 Inhibitor basierend auf HR+/HER2- Profil. Konkrete Wirkstoffauswahl nach Verfügbarkeit und Patientenfaktoren.</p>\n</div></blockquote></div>"
  },
  "status" : "active",
  "intent" : "option",
  "medicationCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://fhir.de/CodeSystem/bfarm/atc",
        "code" : "L01EF",
        "display" : "Cyclin-abhängige Kinasen (CDK)-Inhibitoren"
      }
    ],
    "text" : "CDK4/6 Inhibitor (Klasse L01EF) - Palbociclib, Ribociclib oder Abemaciclib"
  },
  "subject" : {
    🔗 "reference" : "Patient/mii-exa-onko-molecular-board-patient"
  },
  "authoredOn" : "2024-01-15",
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/primaertumor-example"
    }
  ],
  "note" : [
    {
      "text" : "Molekulares Tumorboard empfiehlt beliebigen CDK4/6 Inhibitor basierend auf HR+/HER2- Profil. Konkrete Wirkstoffauswahl nach Verfügbarkeit und Patientenfaktoren."
    }
  ]
}